05/08/2025
We’re delighted that Dysplasia has recently joined Babraham Research Campus, bringing their expertise and innovation to our LiveLabs Community!
About Dysplasia
Dysplasia Diagnostics Limited is developing innovative, affordable, AI-driven RNA blood profiling technologies designed for early cancer detection, personalized treatment monitoring, and the timely identification of drug resistance and relapse. Our mission is to revolutionise cancer care by expanding access to comprehensive screening and providing precise patient insights through diagnostic and therapeutic dashboards, such as DiNanoQ and DiNanoTrack
Denise Williams, Managing Director at Dysplasia Diagnostics Limited said, “Our experience on campus has been great, we have really valued the support and advice received so far and look forward to the opportunities that being part of the Babraham ecosystem will bring.”
About Babraham Research Campus
Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The aim of the Campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organisations. The Campus provides laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
Please join us in giving Dysplasia a warm welcome—we’re excited to see what’s next!